Duet BioTherapeutics Inc. is a biotechnology company developing novel immunotherapies to overcome treatment-resistant cancers. Duet’s therapeutic candidates selectively and simultaneously activate ...

Your board of directors strongly urges you to re-elect Dr. Hofstein and Dr. Battleman. Your vote in incredibly important at this year’s Annual Meeting. Morris C. Laster, M.D. continues his campaign to ...

Short interest in Scopus BioPharma Inc (OTC:SCPS) decreased during the last reporting period, falling from 10.51K to 10.51K. This put 0.03% of the company's publicly available shares short. Short ...

Explore Scopus BioPharma stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for SCPS. Why AMC Entertainment Shares Are Trading Lower By Around 13%? Here Are 59 ...

NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (OTCQB: “SCPS”) and its majority-owned subsidiary, Duet BioTherapeutics Inc., presented compelling new data that DUET-102 in ...

NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: SCPS) (“Scopus” or the “Company”) today announced that it has filed an amendment to the Current Report on Form 8-K that was ...

Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, ...

NEW YORK, March 15, 2021 /PRNewswire/ — Scopus BioPharma Inc. (Nasdaq: “SCPS”) today announced the finalization of arrangements for the completion of the investigational new drug (“IND”) package for ...

NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”) today announced it will be rescheduling the company’s 2021 Annual Meeting of Shareholders (the “2021 Annual Meeting”), ...

NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (OTCQB: “SCPS”) and its majority-owned subsidiary, Duet BioTherapeutics Inc., presented compelling new data that ...